Stock Events

Stock Events

Devonian Health Group 

C$11.9
1
+C$0.91+8.28% Thursday 15:26

Statistics

Day High
11.9
Day Low
11.9
52W High
684
52W Low
7.8
Volume
-
Avg. Volume
-
Mkt Cap
1.97B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22DecExpected
Q3 2022
-0.01
0.33
0.66
0.99
Expected EPS
N/A
Actual EPS
-0.0069

Financials

-25.49%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
47.18MRevenue
-12.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GSD.V. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap178.43M
Corbus Pharmaceuticals develops innovative therapeutics in the area of inflammatory and fibrotic diseases, overlapping with Devonian's therapeutic areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.74B
Acadia Pharmaceuticals specializes in biopharmaceuticals for central nervous system disorders, a field relevant to Devonian's product development.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.85B
Supernus Pharmaceuticals focuses on CNS diseases, directly competing with Devonian's therapeutic focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals works on RNAi therapeutics, competing in the innovative pharmaceuticals space with Devonian.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals engages in creating new drugs for serious diseases, similar to Devonian's mission in botanical-based therapeutics.
Incyte
INCY
Mkt Cap18.84B
Incyte specializes in oncology and inflammatory diseases, areas that Devonian might target with its botanical drugs.
AMGEN
AMGN
Mkt Cap185.74B
Amgen, a biotech giant, competes broadly in the pharmaceuticals market, including areas that might overlap with Devonian's botanical treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is involved in biopharmaceuticals for a variety of therapeutic areas, potentially competing with Devonian's products.

About

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Show more...
CEO
Dr. Andre P. Boulet Ph.D.
Employees
8
Country
Canada
ISIN
CA2518348834

Listings

OTC Link
US
DVHGF
V
CA
GSD.V

0 Comments

Share your thoughts

FAQ

What is Devonian Health Group stock price today?▼
The current price of GSD.V is C$11.9 CAD — it has increased by +8.28% in the past 24 hours. Watch Devonian Health Group stock price performance more closely on the chart.
What is Devonian Health Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Devonian Health Group stocks are traded under the ticker GSD.V.
What is Devonian Health Group market cap?▼
Today Devonian Health Group has the market capitalization of 1.97B
What is Devonian Health Group revenue for the last year?▼
Devonian Health Group revenue for the last year amounts to 47.18M CAD.
What is Devonian Health Group net income for the last year?▼
GSD.V net income for the last year is -12.03M CAD.
How many employees does Devonian Health Group have?▼
As of April 29, 2026, the company has 8 employees.
In which sector is Devonian Health Group located?▼
Devonian Health Group operates in the Health & Wellness sector.
When did Devonian Health Group complete a stock split?▼
The last stock split for Devonian Health Group was on January 22, 2026 with a ratio of 1:60.
Where is Devonian Health Group headquartered?▼
Devonian Health Group is headquartered in Québec, Canada.